Treatment Algorithm for Stage IB and Beyond NSCLC

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.